GlassScriptPhysician profile
Neeka L Sanders
NPI 1922067107
$9,372.95
in general payments reported to CMS, 2019-2025
22 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $7,420 · 2021: $408 · 2022: $237 · 2023: $367 · 2024: $280 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,530.29 | 2019-2020 | |
| Abbvie INC. | $570.60 | 2020-2025 | Liletta, Qulipta, Lo Loestrin Fe |
| Astellas Pharma US INC | $273.70 | 2023-2025 | Veozah |
| Daiichi Sankyo INC. | $195.93 | 2020-2024 | Injectafer |
| Mayne Pharma Commercial LLC | $115.70 | 2021-2025 | |
| Shield Therapeutics INC | $88.92 | 2023-2025 | Accrufer |
| Aspira Women'S Health INC | $76.79 | 2021 | |
| Hologic Sales and Service, LLC | $71.48 | 2023-2025 | Omni Hysteroscope, Novasure, Acessa Provu System |
| Exeltis, USA INC. | $58.37 | 2020-2025 | Slynd |
| Boston Scientific Corporation | $54.21 | 2024 | Solyx Sis System |
| Organon LLC | $49.34 | 2022-2024 | |
| Applied Medical Resources Corporation | $46.38 | 2023 | Gelpoint V-Path |
| Cumberland Pharmaceuticals, INC. | $42.57 | 2020-2021 | |
| Pfizer INC. | $29.73 | 2021 | |
| Millicent US INC | $29.36 | 2025 | Intrarosa, Femlyv, Femring |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $28.26 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $25.35 | 2024 | Myfembree |
| Lupin INC. | $24.22 | 2019-2021 | |
| Biogen, INC. | $18.90 | 2025 | Zurzuvae |
| Becton, Dickinson and Company | $14.93 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.07 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeka Sanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.